Equillium_Square_Logo.png
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
September 17, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium Announces Proposed Public Offering of Common Stock
August 13, 2020 16:02 ET | Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. Announces a Collaboration with Hospital for Special Surgery (HSS) for Antiphospholipid Syndrome
August 03, 2020 16:05 ET | Exagen Inc.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Equillium_Square_Logo.png
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
July 30, 2020 16:07 ET | Equillium
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium to Present at Jefferies Virtual Healthcare Conference
May 21, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Reports First Quarter 2020 Financial Results
May 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_Square_Logo.png
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
March 30, 2020 16:07 ET | Equillium
LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_Square_Logo.png
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 26, 2020 16:07 ET | Equillium
EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., March ...
Equillium_Square_Logo.png
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
December 09, 2019 16:10 ET | Equillium
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...